[5] Suresh Ramalingam, Terufumi Kato, Xiaorong Dong, et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Pri...
[2]Rui-Hua Xu, Feng Wang, et al. Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study. J Clin Oncol 4...
参考文献 Michael Wang, Wojciech Jurczak, Mats Jerkeman, et al. Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance ...
姓名: Connor Boarman 地區: 美國 參賽次數: 1 WCA ID: 2022BOAR01 性別: 男 參賽經歷: 2022.04.03 - 2022.04.03 2024年度總結 個人最好成績 項目地區排名洲際排名世界排名單次平均世界排名洲際排名地區排名金銀銅復原/嘗試 3x3x3方塊 31449 41463 150568 30.11 37.06 152096 42074 31948 5/5...
Cancer Cell 杂志于 2022 年 12 月 22 日在线发表了由北京大学肿瘤医院詹启敏院士团队与放疗科王维虎教授团队合作开展的肠道微生物影响直肠癌新辅助放化疗疗效的前沿研究成果。本研究发现普通拟杆菌介导的核苷酸合成能通过促进肿瘤细胞的 DNA 修复,从而影响局部晚期直肠癌新辅助治疗的疗效,揭示了肠道微生物影响直肠癌新辅...
Cancer Cell 杂志于 2022 年 12 月 22 日在线发表了由北京大学肿瘤医院詹启敏院士团队与放疗科王维虎教授团队合作开展的肠道微生物影响直肠癌新辅助放化疗疗效的前沿研究成果。本研究发现普通拟杆菌介导的核苷酸合成能通过促进肿瘤细胞的 DNA 修复,从而影响局部晚期直肠癌新辅助治疗的疗效,揭示了肠道微生物影响直肠癌新辅...
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures. Expert Help Earn Rewards Cart, contains 0 items Up to 50% Off Fall Gear & Apparel ...
13% of wins 56% of losses Submission 48 wins, 2 losses W L 79% of wins 11% of losses Decision 5 wins, 6 losses W L 8% of wins 33% of losses MMA Record By Promotion 2014TO2022 9 win 8 0 draw 0 no contest 1 7 1
Ranging from the lofty alpine zones of the Canadian Rockies to the tight glades of Vermont's Green Mountains, the Burton Ion Boa Snowboard Boot always brings us the aggressive flex and uncompromising support we've come to expect from Burton's flagship all-terrain boot. The Ion Boa lends itsel...
不管是在 CPS≥5 人群,还是在所有的随机人群,信迪利单抗联合化疗对比化疗 OS、PFS 及 ORR 都有显著的获益且未发现新的安全信号。2022 年 CSCO 胃癌指南根据 ORIENT-16 研究发表的数据推荐信迪利单抗联合化疗方案作为晚期或转移性胃/胃食管结合部腺癌患者的...